SEQUA.BR Sequana Medical NV
- Market cap
- EUR 47.8M
- P/E
- -
- P/B
- 9.22x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 0.2/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2025.
Is SEQUA.BR undervalued?
Graham numberThe Graham number of Sequana Medical NV cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sequana Medical NV fundamental analysis
1 of 21 checks passedROE 0/2
ROE cannot be calculated: equity is negative or not reported.
ROA 0/1
Return on assets (-501.8%) is below the industry median (2.0%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-0.3%) is below the industry median (10.1%).
Revenue Growth 0/2
Revenue shrank 34.1% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (9.2x) is above the industry median (1.7x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Sequana Medical NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sequana Medical NV
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headq…
Full company profileSequana Medical NV financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sequana Medical NV annual financial statements
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.68M | 1.49M | 1.30M | 1.03M | 971K | 963K | 371K | 923K | 712K | 106K | - |
| Gross Profit | 1.33M | 1.17M | 1.09M | 871K | 773K | 761K | 294K | 718K | 548K | -2.22M | -2.30M |
| Operating Income | -11.4M | -13.7M | -7.57M | -13.0M | -14.1M | -17.5M | -22.6M | -28.1M | -29.5M | -18.7M | -35.9M |
| EBITDA | -11.4M | -13.7M | -7.49M | -13.0M | -13.8M | -17.6M | -22.2M | -29.7M | -28.8M | -17.4M | -19.3M |
| Net Income | -11.6M | -14.0M | -8.23M | -14.0M | -15.0M | -19.1M | -23.6M | -30.8M | -32.6M | -44.7M | -73.1M |
| EPS | -0.85 | -1.02 | -0.60 | -1.02 | -1.22 | -1.25 | -1.30 | -1.35 | -1.22 | -1.22 | -1.91 |
| Balance Sheet | |||||||||||
| Total Assets | 4.68M | 3.81M | 3.52M | 3.34M | 9.35M | 14.2M | 14.7M | 26.0M | 10.1M | 9.94M | 14.6M |
| Total Liabilities | 4.97M | 10.5M | 8.13M | 22.1M | 8.42M | 14.1M | 15.5M | 28.2M | 29.6M | 54.3M | 53.7M |
| Shareholders' Equity | -285K | -6.67M | -4.61M | -18.8M | 926K | 113K | -787K | -2.15M | -19.5M | -44.4M | -39.2M |
| Cash & Short-term Investments | 1.43M | 797K | 1.68M | 1.32M | 5.59M | 11.0M | 9.60M | 18.9M | 2.58M | 3.81M | 7.31M |
| Total Debt | - | 4.66M | 4.58M | 14.7M | 3.22M | 7.86M | 8.09M | 17.6M | 17.5M | 40.1M | 41.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -11.3M | -12.7M | -8.69M | -9.88M | -18.5M | -17.0M | -23.6M | -27.5M | -29.1M | -20.3M | -39.7M |
| Capital Expenditure | 88.8K | 215K | 6.52K | 38.6K | 333K | 138K | 326K | 677K | 711K | 95.0K | 8.00 |
| Free Cash Flow | -11.3M | -13.0M | -8.70M | -9.91M | -18.8M | -17.1M | -23.9M | -28.2M | -29.8M | -20.5M | -39.7M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -1,617.6% | -16,943.8% | - | - | - | - | - |
| ROA | -246.8% | -367.0% | -233.7% | -418.5% | -160.2% | -134.4% | -160.6% | -118.2% | -322.4% | -449.1% | -501.8% |
| Net Profit Margin | -685.9% | -938.7% | -630.8% | -1,358.7% | -1,543.1% | -1,983.5% | -6,373.8% | -3,334.1% | -4,572.4% | -42,126.4% | - |
| Debt to Equity | - | - | - | - | 3.48x | 69.70x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sequana Medical NV dividends
Sequana Medical NV has not paid dividends in the last 9 fiscal years.
Who owns Sequana Medical NV
- Insiders 9.59%
- Institutions 30.20%
- Public & others 60.21%
- Shares outstanding 78.2M
- Free float 40.7M
Sequana Medical NV company profile
- Company name
- Sequana Medical NV
- Ticker
- SEQUA.BR
- ISIN
- BE0974340722
- Exchange
- Euronext Brussels
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 48
- Fiscal year end
- December
- Address
- Kortrijksesteenweg 1112, Gent, Belgium, 9051
- Phone
- 32 9 292 8065
- Website
- sequanamedical.com
About Sequana Medical NV
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.
Sequana Medical NV management
5- Mr. Ian CrosbieCEO & Executive Director
- Ms. Kirsten Van BockstaeleChief Financial Officer · born 1975
- Dr. Gijs Klarenbeek M.D.MD & Chief Medical Officer · born 1977
- Mr. Martijn BlomChief Commercial Officer · born 1974
- Mr. Mark SingerHead of U.S. Commercial